AbbVie to unveil new data at 2025 ASH Congress on blood cancer treatments.

AbbVie will present new data at the 2025 American Society of Hematology (ASH) Congress showcasing advances in research across multiple blood cancers. The data highlights the company's breadth and depth of research in therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors, and Antibody-Drug Conjugates. New data will be presented for investigational compounds etentamig (ABBV-383) and PVEK (pivekimab sunirine), as well as approved therapies EPKINLY and VENCLEXTA.